Period:
Draw Mode:
| Volume | 249,882 |
|
|||||
| News | - | ||||||
| Day High | 0.94 | Low High |
|||||
| Day Low | 0.8372 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Context Therapeutics Inc | CNTX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.06 | 6.82% | 0.94 | 11:20:23 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.90 | 0.8372 | 0.94 | 0.88 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 264 | 249,882 | $ 0.8872937 | $ 221,719 | - | 0.47 - 2.52 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 11:16:47 | 295 | $ 0.94 | USD |
Context Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 15.01M | 15.97M | 13.59M | $ - | $ - | -0.40 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 37.12k | 1.90% |
Context Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CNTX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.6357 | 0.94 | 0.6357 | 0.8155439 | 492,424 | 0.3043 | 47.87% |
| 1 Month | 0.56 | 0.94 | 0.47 | 0.7142852 | 186,835 | 0.38 | 67.86% |
| 3 Months | 0.754 | 0.94 | 0.47 | 0.6813423 | 122,675 | 0.186 | 24.67% |
| 6 Months | 1.45 | 1.55 | 0.47 | 0.9623968 | 1,083,075 | -0.51 | -35.17% |
| 1 Year | 2.02 | 2.52 | 0.47 | 1.16 | 690,659 | -1.08 | -53.47% |
| 3 Years | 4.44 | 10.87 | 0.47 | 4.02 | 1,254,753 | -3.50 | -78.83% |
| 5 Years | 4.44 | 10.87 | 0.47 | 4.02 | 1,254,753 | -3.50 | -78.83% |
Context Therapeutics Description
| Context Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. |